Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Launched by UNIVERSITY OF COLOGNE · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for early-stage classical Hodgkin Lymphoma (cHL), which is a type of cancer that affects the lymphatic system. The researchers are looking at using a drug called pembrolizumab, an anti-PD-1 antibody, along with radiotherapy, to create a treatment plan that doesn’t involve chemotherapy. This could potentially make the treatment easier and less harsh for patients who have just been diagnosed with this type of lymphoma.

To participate in the trial, patients should be between the ages of 18 and 65 and have a confirmed diagnosis of early-stage cHL (stage I or II) without certain risk factors, such as having a large mass in the chest or involvement of multiple lymph nodes. However, people with other types of lymphoma, those who have received previous treatments for cHL, or those who are pregnant or breastfeeding cannot join. The trial is not yet recruiting participants, but once it starts, those who qualify can expect to receive the combination of pembrolizumab and radiotherapy as part of their treatment plan, with the goal of improving their chances of recovery without the need for chemotherapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven first diagnosis of cHL
• • Stage I-II without risk factors
• • Large mediastinal mass
• • Extranodal involvement
• • Elevated erythrocyte sedimentation rate (ESR)
• • Involvement of ≥ 3 nodal areas
• Exclusion Criteria:
• • Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,
• • Prior cHL-directed treatment
• • Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant
• • Prior or concurrent disease precluding protocol treatment (for details see section 4.2)
• • Pregnancy or breastfeeding
• • Non-compliance